LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial

Immune checkpoint blockade (ICB) added to neoadjuvant chemotherapy (CTx) improves outcome for early stage TNBC patients, but it is largely unknown which patients truly benefit from ICB and for whom CTx can be de-escalated. Moreover, the addition of anti-CTLA4 to anti-PD1 has not been explored in early TNBC. In the first two cohorts of the adaptive phase II BELLINI trial we test the hypothesis that 4 weeks of neoadjuvant nivolumab (nivo) ± low dose ipilimumab (ipi, 1mg/kg) can induce immune responses in TNBC harboring TILs (TILs≥5%).